PRMT5 and neoplasm: Here, we demonstrate that BCSCs are more resistant to cisplatin and radiotherapy-induced cell death compared to the bulk tumour population, repair damaged DNA more efficiently than bulk cells, and that this is dependent on PRMT5 activity.